ro 31-8425 has been researched along with Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alaamery, M; Alhasan, AH; De Biasio, M; Heinelt, M; Karp, JM; Kenison, JE; Kuai, R; Kuang, H; Lan, H; Levy, O; Majid, T; Mascanfroni, I; Massadeh, S; Milton, Y; Multon, MC; Musabeyezu, J; Perrault, C; Quintana, FJ; Rothblatt, J; Rothhammer, V; Safaee, H; Siders, W; Tong, Z; Wang, Q; Yeste, A | 1 |
| Pozo, D | 1 |
2 other study(ies) available for ro 31-8425 and Multiple Sclerosis
| Article | Year |
|---|---|
A cell-based drug delivery platform for treating central nervous system inflammation.
Topics: Animals; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Humans; Immunity; Indoles; Maleimides; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Multiple Sclerosis; T-Lymphocytes; Tissue Distribution; Transplantation, Heterologous; Treatment Outcome | 2021 |
Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration.
Topics: Animals; Autoimmunity; Drug Delivery Systems; Encephalomyelitis, Autoimmune, Experimental; Humans; Indoles; Maleimides; Mesenchymal Stem Cells; Mice; Multiple Sclerosis; Transplantation, Heterologous; Treatment Outcome | 2021 |